ABVX Share Price Performance
€104.20
97.08 (1,363.48%)
Price €104.20
Share Pricen/a
ABIVAX Société Anonyme Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
ABVX Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
ABIVAX Société Anonyme Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- -2.59
- 100.00%
- -3,244.03%
- -200.6%
About ABVX
- Founded
- 2013
- Employees
- 69
- CEO
- WebsiteView website
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.
